Transgene Biotek Intrinsic Value
TRABI Valuation Methods Summary
| Method | Type | Intrinsic Value | Range | Upside/Downside | Details |
|---|---|---|---|---|---|
| Book Value Method | asset | ₹1.32 | ₹1.19 - ₹1.45 | -54.3% | Book Value/Share: ₹1.32, P/B: 1.0x |
Want to compare with current market value? Check TRABI share price latest .
Valuation Comparison Chart
TRABI Intrinsic Value Analysis
What is the intrinsic value of TRABI?
Based on our comprehensive analysis using 1 different valuation methods, the estimated intrinsic value of Transgene Biotek (TRABI) is ₹1.32 (median value). With the current market price of ₹2.89, this represents a -54.3% variance from our estimated fair value.
The valuation range spans from ₹1.32 to ₹1.32, indicating ₹1.32 - ₹1.32.
Is TRABI undervalued or overvalued?
Based on our multi-method analysis, Transgene Biotek (TRABI) appears to be trading above calculated value by approximately 54.3%.
Financial Health Analysis
| Financial Metric | Current Value | Industry Benchmark | Assessment | Impact on Valuation |
|---|---|---|---|---|
| Current Ratio | 0.01 | Industry Standard: 2.0+ | Below 1.5 | Measures short-term liquidity capacity |
| Debt to Equity Ratio | 14.40 | Industry Standard: <0.5 | Above 1.0 | Indicates financial leverage level |
| Operating Margin | -160.0% | Industry Standard: 20%+ | Below 10% | Indicates operational efficiency level |
Related Pages for Transgene Biotek
Additional stock information and data for TRABI
Cash Flow Quality Analysis
| Period | Operating Cash Flow | Free Cash Flow | Cash Flow Quality | Sustainability Score |
|---|---|---|---|---|
| March 2025 | ₹1 Cr | ₹0 Cr | Positive Operating Cash Flow | 6/10 |
| March 2024 | ₹0 Cr | ₹0 Cr | Negative Cash Flow | 3/10 |
| March 2023 | ₹0 Cr | ₹0 Cr | Negative Cash Flow | 3/10 |
| March 2022 | ₹0 Cr | ₹0 Cr | Negative Cash Flow | 3/10 |
| March 2021 | ₹0 Cr | ₹0 Cr | Negative Cash Flow | 3/10 |